BioWorld looks at translational medicine, including: Finding the next pandemic threat early on; Microglial fresh start helps heal brain trauma; Finding the silent majority; Anatomy study reveals schizophrenia subtypes; Increasing immune activity improves autoimmunity; How cancer cells hibernate…; …And who makes their bed; Blocking trash trashes MSI-hi tumors; New splicing factor implicated in muscular dystrophy.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Agex, Altimmune, Generex, Graybug, Merck, Sonoma, Therapix.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Advaxis, Anokion, Brainstorm, Clene, Gilead, Incysus, Inflazome, Iteos, Mapkure, Neurimmune, Polypid.
Rated the No. 1 most prepared country in the world to tackle an epidemic, the U.S. could see its preparedness put to the test as it responds to the growing COVID-19 outbreak. While the administration is pointing to that rating from a recent global survey to calm fears about the risk in the U.S., the coronavirus emergency is spotlighting cracks in the nation’s preparedness.
LONDON – The COVID-19 epidemic has reached a “decisive point” as the number of new cases in the rest of the world exceeded the number of new cases in China, and seven countries reported infections for the first time.
BEIJING – There was encouraging news when vaccine developer Moderna Inc. announced this week it that has shipped the first vials of its mRNA vaccine against COVID-19 for a phase I trial in the U.S. The vaccine was created just 42 days after the genetic sequence of the COVID-19 virus was released. That is record speed. Other vaccine developers are also working around the clock to respond to the epidemic.
With the CDC saying Tuesday that it’s not if but when COVID-19 becomes more widespread in the U.S., now is not the time to cut the budgets of programs and agencies in the Department of Health and Human Services (HHS).
DUBLIN – Could a recombinant human protein drug rejected by Glaxosmithkline plc in 2019 benefit patients with COVID-19 infection? Apeiron Biologics AG disclosed Wednesday Feb. 26 that an investigator-initiated pilot study of APN-01 is getting underway in Guangzhou, China.
RSS
